Patients with AIH may exhibit features of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), or a cholestatic syndrome in the absence of objective features of PBC or PSC (6).

Autoimmune liver diseases (AILD) comprise a group of immune-mediated liver diseases that include autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) . Each of them are distinct entities, although they share some similarities clinicopathologically .

Her autoimmune workup is notable for findings seen in both autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC); hence an overlap syndrome should be evaluated with a liver biopsy. The correct dosing of UDCA for PBC is 13-15mg/kg/day.

Autoimmune Hepatitis (AIH) and Primary Biliary Cirrhosis (PBC) are important immune mediated liver diseases. They are usually differentiated based on clinical, biochemical, serological and histological parameters.

Feb 1, 2007 · Although most cases of autoimmune liver disease fit readily into one of these three categories, overlap syndromes (primarily of AIH with PBC or PSC) may comprise up to 10% of cases, and variant...

May 28, 2019 · Patients with autoimmune liver disease frequently fit diagnostic criteria for more than one condition. Up to 12.5% of autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC) cohorts have a label of AIH/PSC overlap.

Clinicians thus encounter individuals with biochemical, serological, and histological manifestations that are common to both primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH), often labelled as ‘PSC/AIH-overlap’.

Autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), and primary biliary cirrhosis (PBC) are chronic autoimmune liver diseases. Overlap syndrome is defined as a condition in which...

Immune-mediated liver diseases including autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are rare. Overlap between these entities comprises an even smaller group with AIH-PBC being the most common.

Das Overlap-Syndrom zwischen AIH und PBC wird symptomatisch mit hochdosierter Ursodesoxycholsäure sowie der o.a. immunsuppressiven Kombinationstherapie behandelt. Langzeitergebnisse aus prospektiv randomisierten Studien liegen bislang nicht vor.